Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
A biopharmaceutical company developing innovative therapeutics
in the fields of oncology and infectious diseases
(TSX:AMB)...
This presentation contains forward-looking statements that reflect the Company’s
current expectation regarding future even...
3
Investment Highlights
 Lead HIV/AIDS proprietary product licensed to
top Pharma, Merck & Co. for $17 million upfront,
p...
4
(1) Licensed to Mallinckrodt (U.S.), TEVA (France, Germany, Benelux, Spain, Scandinavia), Archimedes
Pharma (U.K.), Gero...
5
Ambrilia & Merck: Licensing Agreement
Terms
• Merck receives exclusive worldwide rights to Ambrilia’s
HIV/AIDS PI Progra...
6
PPL-100: Market potential
• HIV/AIDS market(1)
estimated to reach US$ 9 billion at
the projected time of launch of PPL-1...
7
PPL-100: Phase I
• Phase I single dose escalation study in healthy volunteers
--- Estimated protein binding adjusted EC9...
8
PPL-100: Next Steps
• Phase 1 repeat dosing study in healthy volunteers
completed by Ambrilia
 Good safety profile: onl...
Significant near-term product
revenues from new formulations
of existing drugs
10
Oncology: Improved formulation of Octreotide
• Therapeutic alternative to Novartis’ Sandostatin®
LAR
(somatostatin anal...
11
Mean plasma concentrations in healthy volunteers (12/12)
0
500
1000
1500
2000
0 7 14 21 28 35 42 49 56 63
Days
Octreoti...
12
Calculation supports use of C2L every 6 weeks
Third
injection
C2L (42D) vs SLAR (28D)
1
1000
0 20 40 60 80 100 120 140
...
13
Octreotide: Clinical Plan
• Limited Phase 3 clinical studies
• in Europe and in the U.S.
• 3 months activity + 3 months...
14
Octreotide: Marketing Strategy
• Ambrilia manufactures and will sell the finished product to
its licensees, at contract...
15
Oncology: New formulation of Goserelin
• Potential first-to-market therapeutic alternative to
Astra Zeneca’s Zoladex LP...
16
Goserelin: Developments
• Upcoming Milestones
• In house formulation optimization Ongoing
• Human PK study, single dose...
Proprietary products in
cancer and infectious diseases
18
Oncology: PCK3145
• Therapeutic anti-cancer peptide with signal transduction
mediated effects on tumor metastasis
• Ind...
19
PSP94 Test: Novel Biomarker Assay
• A test to measure the plasma levels of PSP94, a
powerful new prostate cancer progno...
20
Oncology: TVT (Tumor Vasculature Targeting) Platform
• NGR peptides-based targeted drug delivery technology that delive...
21
HIV Integrase Inhibitor Program
• Integrase Inhibitor is a high-profile platform for the
treatment of HIV/AIDS
• Merck ...
22
Financial Snapshot
Ticker Symbol (TSX) AMB
Recent share price CDN$ 3.00
Market capitalization ~ CDN$ 87 M
Shares outsta...
23
AMB-T vs. U.S. & C.A. Biotech Indices
60
80
100
120
140
160
180
200
220
01-mars-06
22-mars-06
12-avr-06
04-mai-06
26-ma...
24
Management Team
Hans J. Mäder
President & CEO
Held numerous senior
executive positions at
Sandoz / Novartis.
Monique Lé...
25
Summary – Upcoming Milestones
2007
• PPL-100 – Out-licensing 
• Octreotide - Start of clinical trials 
• PCK 3145 - C...
A biopharmaceutical company developing innovative therapeutics
in the fields of oncology and infectious diseases
(TSX:AMB)...
Upcoming SlideShare
Loading in …5
×

A biopharmaceutical company developing innovative ...

950 views

Published on

  • Be the first to comment

A biopharmaceutical company developing innovative ...

  1. 1. A biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases (TSX:AMB) Corporate Presentation Last update March 14, 2007
  2. 2. This presentation contains forward-looking statements that reflect the Company’s current expectation regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company’s filings. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia’s products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia’s views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements.‑ Ambrilia’s Forward-Looking Statements
  3. 3. 3 Investment Highlights  Lead HIV/AIDS proprietary product licensed to top Pharma, Merck & Co. for $17 million upfront, potential $212 million (U.S.) in milestones, and royalties  Near-term product revenue opportunities from two new formulations of existing drugs, Octreotide and Goserelin 2 leading Pharma companies as licensees, TEVA and Mallinckrodt, of improved formulation of Octreotide Product pipeline addressing infectious disease and cancer
  4. 4. 4 (1) Licensed to Mallinckrodt (U.S.), TEVA (France, Germany, Benelux, Spain, Scandinavia), Archimedes Pharma (U.K.), Gerolymatos (Greece, Turkey, other export countries), Kwidza Pharma (Austria), Pharmis (Portugal, Brazil) (2) Licensed to Merck & Co. worldwide Pipeline Overview
  5. 5. 5 Ambrilia & Merck: Licensing Agreement Terms • Merck receives exclusive worldwide rights to Ambrilia’s HIV/AIDS PI Program, incl. lead compound PPL-100 • Upfront licensing fee: $US 17M, additional milestones: $US 212M • Royalties on sales • Merck assumes all future development costs • Potential additional payments and royalties on development and commercialization of each related compound
  6. 6. 6 PPL-100: Market potential • HIV/AIDS market(1) estimated to reach US$ 9 billion at the projected time of launch of PPL-100 (2012) • PIs: a healthy 1/3 of the HIV/AIDS treatment options - Today’s Market leader Abbott’s Kaletra® : US$ 1.0 B(2) • PPL-100 market share and revenues expected to be significant based on its competitive advantages:  Excellent safety and tolerability  Favorable cross-resistance profile  High genetic barrier  Potential once-a-day dosage, ritonavir free (1) Decision Resource – 2004 HIV Infectious Diseases Study #68, Frost & Sullivan 2004 Strategic Analysis World HIV Market, 2006 DataMonitor - Pipeline Insight HIV (2) Life Science Analytics – Medtrack Database
  7. 7. 7 PPL-100: Phase I • Phase I single dose escalation study in healthy volunteers --- Estimated protein binding adjusted EC90 against wild-type virus (~ 40-60ng/mL) Ctrough for both 600mg and 1200mg doses above EC90 0 4 8 12 16 20 24 10 100 1000 600 mg 600 mg + light meal Time (h) PlasmaPL-100(ng/mL) 0 4 8 12 16 20 24 10 100 1000 1200 mg 1200 mg + light meal Time (h) PlasmaPL-100(ng/mL) C24 ~ 67 ng/mL C24 ~ 75 ng/mL
  8. 8. 8 PPL-100: Next Steps • Phase 1 repeat dosing study in healthy volunteers completed by Ambrilia  Good safety profile: only mild (grade 1) adverse events and no moderate or severe cardiovascular, lipidic or hepatic adverse events observed  PK data support the potential for once or twice daily treatment, without ritonavir boosting, for PI-naïve and PI-experienced HIV/AIDS patients • Merck has initiated formulation development • Further development in patients will follow
  9. 9. Significant near-term product revenues from new formulations of existing drugs
  10. 10. 10 Oncology: Improved formulation of Octreotide • Therapeutic alternative to Novartis’ Sandostatin® LAR (somatostatin analogue) • Indicated for acromegaly and some digestive tumors • 2006 Sandostatin® sales(1) : ~ $US 1B (+ 4 %), over 70% for the LAR • Three dosages of LAR: 10, 20 and 30 mg per unit • 30mg (over 50% of market) sells for $US 2,830 per unit • 13 injections needed per year ( $US 25,000 to > $US 36,000) • Improved prolonged release formulation developed with patented technology (C2L)  Much simpler and easier to use  With pharmacokinetic advantages  Manufactured in-house, cGMP compliant (1) Novartis Annual Report 2006
  11. 11. 11 Mean plasma concentrations in healthy volunteers (12/12) 0 500 1000 1500 2000 0 7 14 21 28 35 42 49 56 63 Days Octreotide C2L-oct S LAR Superior bioavailability
  12. 12. 12 Calculation supports use of C2L every 6 weeks Third injection C2L (42D) vs SLAR (28D) 1 1000 0 20 40 60 80 100 120 140 Time (days) Octreotide(pg/ml) TEST SLAR
  13. 13. 13 Octreotide: Clinical Plan • Limited Phase 3 clinical studies • in Europe and in the U.S. • 3 months activity + 3 months safety follow-up • Endpoints: Surrogate marker (Growth Hormone & IGF-1 levels) • Upcoming milestones • Start of clinical studies in acromegaly patients  • Filing in Europe and in the U.S. H1 2008
  14. 14. 14 Octreotide: Marketing Strategy • Ambrilia manufactures and will sell the finished product to its licensees, at contractually fixed price • Licensing agreements concluded with leading companies worldwide • Agreements have been concluded for commercialization and have already generated milestone payments • Mallinckrodt (U.S.), TEVA (France, Germany, Benelux, Spain, Scandinavia), Archimedes Pharma (U.K.), Gerolymatos (Greece, Turkey, other export countries), Kwidza Pharma (Austria), Pharmis (Portugal, Brazil) • C2L to be promoted as improved prolonged release formulation, with three advantages : less expensive, easier to use because more stable product, less frequent injections (8 or 9 instead of 13 per year)
  15. 15. 15 Oncology: New formulation of Goserelin • Potential first-to-market therapeutic alternative to Astra Zeneca’s Zoladex LP® (LHRH analogue) • Indicated for hormone sensitive prostate cancer • 3-month prolonged release formulation developed with patented technology • Zoladex® 2005 sales(1) : US$ 1.0 B (+9%), primarily in Europe (70% for the 3 month formulation) (1) Life Science Analytics – Medtrack Database
  16. 16. 16 Goserelin: Developments • Upcoming Milestones • In house formulation optimization Ongoing • Human PK study, single dose 2007 • Clinical study in prostate cancer patients H2 2007 • Licensing-out H1 2008 • Filing in Europe H2 2008
  17. 17. Proprietary products in cancer and infectious diseases
  18. 18. 18 Oncology: PCK3145 • Therapeutic anti-cancer peptide with signal transduction mediated effects on tumor metastasis • Indicated for hormone-resistant prostate cancer, a condition with very poor prognosis. • Studied in close to 50 patients  Safe, well-tolerated with some disease stabilization observed • Completed initial U.S. pilot study  Improved dosing  Study fully enrolled - Results expected in H1 2007 - Safety confirmed, and potential efficacy signals • Development partnership discussions ongoing
  19. 19. 19 PSP94 Test: Novel Biomarker Assay • A test to measure the plasma levels of PSP94, a powerful new prostate cancer prognosticator  Confirmed diagnostic value in published study in patients with prostate cancer  Confirmed prognostic value in patients with risk of recurrence • The PSP94 kit can help  Avoid biopsies in patients diagnosed with probable prostate cancer  Help follow-up patients in observation before deciding to treat • Partnership negotiations ongoing • Potential launch in Europe in 2007
  20. 20. 20 Oncology: TVT (Tumor Vasculature Targeting) Platform • NGR peptides-based targeted drug delivery technology that delivers anti-cancer drugs to the vasculature of solid tumors and surrounding tumor cells  Technology consists of a carrier vesicle coated with a tumor homing peptide (NGR) which binds specifically to a receptor (CD13) exclusively expressed in tumor cells and newly formed tumor blood vessels  The carrier is then internalized and releases the anti-cancer drug which, in turn, specifically damages the tumor vasculature and kills the tumor • Targeted NGR peptide can be attached to the surface of liposomes or other nanoparticles loaded with a single or combination of anti-cancer agents • Proof-of-concept with Doxorubicine (Dox) • NGR targeted liposomal Dox with convincing results in animal solid tumors models • Next Steps • Term Sheet negotiation for TVT technology by year-end
  21. 21. 21 HIV Integrase Inhibitor Program • Integrase Inhibitor is a high-profile platform for the treatment of HIV/AIDS • Merck and Gilead have Integrase Inhibitor products in late-stage development for the treatment of HIV • Ambrilia to utilize Integrase Inhibitor Program to develop drugs to treat HIV/AIDS • Status: Lead optimization • Novel structures and new mechanism of action • 12 months to a drug candidate
  22. 22. 22 Financial Snapshot Ticker Symbol (TSX) AMB Recent share price CDN$ 3.00 Market capitalization ~ CDN$ 87 M Shares outstanding 29 M Cash available (Q3/06) Incl. US$ 17 M Merck upfront CDN$ 27.7 M Months of cash (Q3/06) >18 Analyst Coverage BUY Recommendation As of Dec. 01, 2006 David Martin, Dundee Securities Nigel deGruyther, LOM Douglas Loe, Versant Partners
  23. 23. 23 AMB-T vs. U.S. & C.A. Biotech Indices 60 80 100 120 140 160 180 200 220 01-mars-06 22-mars-06 12-avr-06 04-mai-06 26-mai-06 16-juin-06 10-juil-06 31-juil-06 22-août-06 13-sept-06 04-oct-06 26-oct-06 16-nov-06 07-déc-06 02-janv-07 StockPrice(3/01/2006=100) AMB NBI BTK TTHC Since 3/01/06: AMB-T +73.9% Nasdaq Biotech Index (NBI): -4.0% Amex Biotech Index (BTK): +5.0% S&P/TSX Capped Healthcare Index (TTHC): -8.2%
  24. 24. 24 Management Team Hans J. Mäder President & CEO Held numerous senior executive positions at Sandoz / Novartis. Monique Létourneau, CFA, M.Sc., Exec. VP, Finance & CFO Formerly held financial executive positions with Power Corporation of Canada and M&A Group at Deloitte and Touche. Bonabes de Rougé, M.D. Senior Exec. VP & CSO Formerly President and Chief Executive Officer of Cellpep S.A. Chandra J. Panchal, Ph.D. Exec. VP, Bus. Develop., Licensing & IP Co-founder of Procyon, scientist and former group leader at John Labatt Ltd. Richard La Rue, LL.L, D.D.N. VP, Legal Affairs, HR & Corporate Secretary Lawyer with > 30 yrs of national and international experience as a private practitioner and corporate counsel.
  25. 25. 25 Summary – Upcoming Milestones 2007 • PPL-100 – Out-licensing  • Octreotide - Start of clinical trials  • PCK 3145 - Clinical results (4 months exposure) H1 • PSP94 Assay – Licensing • TVT technology - Term-sheet negotiation H2 2008 • Octreotide – Regulatory filing worldwide H1 • Goserelin – Out-licensing H1 • Goserelin – Regulatory filing Europe H2 • TVT – 2nd pay-load out-licensing H2 2009 • Octreotide – Worldwide launch • Goserelin – European launch • TVT – 3rd pay-load out-licensing
  26. 26. A biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases (TSX:AMB) www.ambrilia.com

×